Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130020/S005

Senographe Pristina 3D

GE Healthcare · Decision date Nov 21, 2025

FDA DECISIONP130020/S005

What did the FDA approve?

FDA records P130020/S005 as a supplement to PMA P130020, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 21, 2025.

FDA approval order statement

Approval for Senographe Pristina 3D that includes an update to the DBT reconstruction algorithm to enhance image quality using deep learning algorithms to correct sparse view artifacts, compensate for patient motion artifacts and enhance the visibility of soft tissue lesions within the 2D synthetic image.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Radiology
Decision date
Nov 21, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P130020/S005
Regulatory pathway
PMA supplement
Applicant
GE Healthcare
Product code
OTE
Decision code
APPR
Decision date
Nov 21, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Digital breast tomosynthesis.

Applicant
GE Healthcare
Product code
OTE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130020/S005 received

    Application receipt date recorded by FDA.

  2. P130020/S005 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P130020. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code OTE

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Medical Solutions USA, Inc.PMA supplementJul 1, 2026FDA
Hologic, Inc.PMA supplementNov 24, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

GE Healthcare

Headquarters
Not reported
Brand website
gehealthcare.com
FDA applicant address
3000 N. Grandview Blvd., Waukesha, WI, 53188

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records